INTRODUCTION
As one of the world's leading pharmaceutical companies, AstraZeneca's business is focused on turning good ideas into innovative, effective medicines that make a real difference in important areas of healthcare. A major challenge facing pharmaceutical Research and Development (R&D) is the fierce competition, which leads to the urgency of shortening the product development time frame. As a result, any process improvement that can speed up the delivery of a candidate drug is of great benefit to the company. To further this aim, Compound Management Group (CMG) set out to develop an advanced platform for the rapid acquisition of project-driving data that will enable the company to make informed decisions about the future direction of a research project.
Compound Management is a department within R&D Boston whose aim is to curate the potential new medicines (compounds) and to deliver these compounds to research teams on request. Research teams, who are the internal customers of CMG, require compounds in both solid and liquid form. Before the workflow re-design project was started, liquid handling was slow and had an inflexible delivery format. For example, all compounds were delivered in one of only four formats, as it was not possible for CMG to generate assay-ready plates. Also, because compounds were solubilized only once a week, there was often a 7-to 8-day delay between synthesis of a compound and its availability as a liquid. Further, there was no cherry-picking capability; so bioscience departments frequently had no option but to test all the compounds that they received, often wasting time and resources and gathering data on irrelevant compounds. Clearly, a change was needed. 
MATERIALS AND METHODS
The New Solubilization Process Compound Receipt and Solubilization. Once chemists finish synthesizing a new compound, they place it in a collection bin located centrally in each chemistry lab. Then, compounds are collected from the bins twice daily. On collection, CMG weighs the compounds in a robot-friendly vial for local solubilization, and final preparations are made to ship these compounds to a central CMG location for global distribution.
A custom-made high-capacity rack mounted to an integrated shaker mixes the compounds with the appropriate solvent, to the specified concentration. The shaker, shown in Figure 1 , replaces the magnetic stir bars previously used for mixing the solutions. The shaker is mounted on a Tecan Evo (Tecan US, Inc., Durham, NC). Using a shaker is a more efficient method of mixing because the vortex generated by the orbit is much stronger and more efficient than stir disks. To ensure that compounds are in solution, the operator removes the rack from the shaker and visually scans the vials through holes in the custom racks. Previous methods required each vial to be removed for inspection, a time-consuming process. This new method significantly decreases processing time, and also increases throughput.
On solubilization, the robot transfers each solubilized sample to four two-dimensional barcoded tubes. Custom software applications determine the amount of compound to be placed in each tube, helping to facilitate downstream processing. The tool also maximizes the amount of compound generated by decreasing the dead volume in the source vial. A conceptual diagram is shown in Figure 2 . After the aliquots are prepared, the tubes are uploaded to the database, after which they become available for ordering.
Processing Liquid Orders
Cherry-Picking/Formatting. Once compounds are available for ordering, an internal customer places an order for select compounds. Tubes of the given compound are cherry-picked by a BioMicroLab XL-20 (BioMicro Lab Inc., Concord, CA) and re-arrayed into a rack. Racks full of cherry-picked tubes are then either delivered, or further processed into assay-specific formats using a Tecan Evo or a Tecan Genesis. A conceptual workflow diagram contrasting the previous and current systems is shown in Figure 3 .
Through in-house development of software tools for plating compounds, CMG has greatly increased its flexibility with regard to output plate formats. Custom applications allow CMG to readily respond to requests for individualized plate types and formats. New formats and protocols are usually production-ready in less than a week. For the scientist, this upstream processing of compound plates greatly reduces their preparation time and allows for higher capacity runs.
RESULTS

Time to Process Orders Decreases Dramatically
Within one month of the launch of the new workflow, which includes the custom hardware and software applications, the time taken to process both liquid and solid orders decreased dramatically. The average time to complete solid orders, which fell to 20 h in December 2007, is shown in Figure 4 . The impact of the new changes is especially notable in the liquid order data, because most of the process improvements were directed toward liquid samples. Liquid order processing time is substantially reduced, even with the additional processing of compounds to assay-specific formats. Solid order processing time also shows improvement; however, not as dramatically as liquid orders. This is primarily due to a drop in the number of solid compounds per order.
Increase in Number of Liquid Orders Handled. There was a remarkable decrease in the time it takes to process liquid orders, despite the fivefold increase in the number of liquid orders handled (shown in Fig. 5 ). Before May 2007, an average of 20.8 liquid orders were handled per month, but postlaunch, an average of 196.5 liquid orders were handled per month. Not only was there a marked increase in orders, but also a substantial increase in the formats. At the project onset, there were only four assay-specific formats. Over the course of the first three months postlaunch, the number of plate formats had increased to more than 20. Fig. 6 ) resulted in CMG exceeding the goal of delivering solid orders in 24 h or less, while simultaneously being able to reduce the number of staff processing solid-sample requests.
Global Compound Availability. Within one week of solubilization, compounds are available for ordering by any AZ employee worldwide. This rapid turnaround allows expedited screening of compounds through multiple projects, across multiple sites. This quick turnaround from synthesis to Figure 3 . The major flaws in the previous were identified and corrected in the current system. Flaws and their solutions are marked in yellow boxes, with flaws on the left under ''previous'', and solutions on the right under ''current''. One major problem with the previous system was that the huge bolus of weighings for the weekly solubilization run slowed down the whole process. This was resolved in the current system by weighing for solubilization daily. availability helps to greatly reduce the compound development timeline. In an industry where speed is of utmost importance, this turnaround time is exceptional. Every week by which the development time can be decreased has an impact on the speed by which differentiated medicines can be brought to the clinic.
Significant Investment in IT Required. As planning for the project's changes unfolded, it became apparent that a significant investment in software development was required. The authors from CMG worked closely with Discovery Informatics (DI) to develop and test the new system. The new underlying IT infrastructure, which consisted of making numerous modifications to the existing in-house software, required a significant investment of time over a period of months. All the participants were also required to partake in a User Acceptance Testing before the product launch.
DISCUSSION
As pharmaceutical companies continue to grow into increasingly large global entities, the ability to curate compounds for global testing is a growing challenge. Companies with sites around the globe must invest heavily in infrastructure to facilitate efficient distribution of compounds to all R&D sites. This undertaking involves major investment in ITrelated applications for the tracking, archiving, and locating of compounds that are dispersed around the globe. In addition, pharmaceutical companies need the appropriate hardware to support the physical distribution and reformatting of the compounds into assay-ready plates. Of course, there are risks associated with the investments put forth into these endeavors. With the rapid discovery of new technology in scientific fields in general, plus the high obsolescence rate of equipment, major overhauls of these systems are required on average every 5e10 years. Continued improvements and enhancements are needed to keep up with the pace of changes in technologies and methodologies.
CONCLUSIONS
Shifting the focus from solid to liquid distribution has dramatically improved the efficiency of AstraZeneca Boston's CMG. Customization of liquid-handling robots, and the development of in-house software were major factors in this improvement. Specifically, whereas before it would take 7e8 days to prepare an in-house sample for testing, in the new process it takes merely 24 h (an 85% reduction in lag time). The custom hardware and robotic deck configurations have made same-day solubilization a reality, decreasing the runtime from 3.5 h/100 compounds down to 45 min/100 compounds. The in-house software applications have allowed CMG to generate assay-ready plates, giving greater flexibility to and saving time for bioscience departments. Despite processing quintuple the number of liquid orders compared with prelaunch, both liquid and solid orders are processed more quickly; and by December 2007, the average was 20 h from solid order placement to delivery. These technological innovations and efficiency improvements enabled CMG to deliver assay-ready plates, and to make compounds available globally. Ultimately, because CMG delivers compounds to the project teams sooner, the time it takes to generate data is markedly reduced.
